IDO1 and neoplasm: (2) Blockade the signals that are inhibiting the recognition (e.g., PD-1/PD-L1 pathway), phagocytosis (e.g., CD47-SIRPα pathway) or the killing of tumor cells (e.g., adenosine and IDO) of immune cells.